New pseudononapeptide bombesin antagonists with C-terminal leu-psi(ch2n)tac-nh2 show high binding-affinity to bombesin/grp receptors on cfpac-1 human pancreatic-cancer cells
- PMID: 21556653
- DOI: 10.3892/ijo.6.6.1165
New pseudononapeptide bombesin antagonists with C-terminal leu-psi(ch2n)tac-nh2 show high binding-affinity to bombesin/grp receptors on cfpac-1 human pancreatic-cancer cells
Abstract
It has been demonstrated that bombesin/GRP antagonist D-Tpi(6),Leu(13)psi(CH2NH) Leu(14)-BN(6-14) (RC-3095) inhibits effectively the growth of pancreatic cancer and other tumors in experimental animals and in cell cultures. In an attempt to develop antagonists with still greater antitumor activity, several new pseudononapeptide bombesin/GRP antagonists containing C-terminal Leu psi(CH2N)Tac-NH2 have been synthesized in our laboratory. In this study, we investigated the ability of four Leu(13)psi(CH2N)Tac(14)-BN(6-14) antagonists to inhibit the binding of bombesin to specific receptors for bombesin/GRP on CFPAC-1 human pancreatic cancer cells. Receptor binding assays were performed by incubating CFPAC-1 cells (5x10(4) cells/well) with 0.5 nM [I-125]-Tyr(4)-bombesin in the absence or presence of (1 pM to 10 mu M) unlabeled bombesin, GRP(14-27) and various antagonists for 2 h at 22 degrees C. Displacement assays showed that antagonist D-Tpi(6),Leu(13)psi(CH2N)Tac(14)-BN(6-14) (RC-3910-II) with a similar structure to RC-3095, but a different C-terminal, had a binding affinity to CFPAC-1 cells 15 times higher than RC-3095. Three other antagonists, RC-3925-II, RC-3940-II and RC-3950-II contained the same C-terminal Leu psi(CH2N)Tac-NH2 as RC-3910-II, but had different N-terminal residues: D-Cpa, Hca and D-Phe, respectively. Among them, Hca(6),Leu(13)psi(CH2N)Tac(14)-BN(6-14) (RC-3940-II) showed the highest binding affinity to the receptors on CFPAC-1 cells, which was 50 times higher than that of RC-3095 or 3 times greater than RC-3910-II. Our findings suggest the merit of further investigation of pseudononapeptide bombesin/GRP antagonist RC-3940-II ind related analogs for a possible development of a new hormonal therapy for pancreatic cancer.
Similar articles
-
Bombesins: A New Frontier in Hybrid Compound Development.Pharmaceutics. 2023 Nov 7;15(11):2597. doi: 10.3390/pharmaceutics15112597. Pharmaceutics. 2023. PMID: 38004575 Free PMC article. Review.
-
New antagonists of bombesin gastrin-releasing Peptide with C-terminal leu-psi-(ch2n)tac-nh2.Int J Oncol. 1995 Oct;7(4):749-54. doi: 10.3892/ijo.7.4.749. Int J Oncol. 1995. PMID: 21552898
-
Effects of new bombesin antagonists given singly or in combination with a somatostatin analog on nitrosamine-induced pancreatic cancers in hamsters.Int J Oncol. 1996 Sep;9(3):397-403. doi: 10.3892/ijo.9.3.397. Int J Oncol. 1996. PMID: 21541526
-
Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives.Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12664-8. doi: 10.1073/pnas.91.26.12664. Proc Natl Acad Sci U S A. 1994. PMID: 7809097 Free PMC article.
-
Systematic development of bombesin/gastrin-releasing peptide antagonists.J Natl Cancer Inst Monogr. 1992;(13):133-9. J Natl Cancer Inst Monogr. 1992. PMID: 1389686 Review.
Cited by
-
Positron Emission Tomography Imaging of the Gastrin-Releasing Peptide Receptor with a Novel Bombesin Analogue.ACS Omega. 2019 Jan 31;4(1):1470-1478. doi: 10.1021/acsomega.8b03293. Epub 2019 Jan 16. ACS Omega. 2019. PMID: 30775647 Free PMC article.
-
Cancer treatment using peptides: current therapies and future prospects.J Amino Acids. 2012;2012:967347. doi: 10.1155/2012/967347. Epub 2012 Dec 20. J Amino Acids. 2012. PMID: 23316341 Free PMC article.
-
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.Cell Cycle. 2012 Jul 1;11(13):2518-25. doi: 10.4161/cc.20900. Epub 2012 Jul 1. Cell Cycle. 2012. PMID: 22751419 Free PMC article.
-
Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3836-41. doi: 10.1073/pnas.052715299. Epub 2002 Mar 12. Proc Natl Acad Sci U S A. 2002. PMID: 11891317 Free PMC article.
-
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):652-6. doi: 10.1073/pnas.94.2.652. Proc Natl Acad Sci U S A. 1997. PMID: 9012839 Free PMC article.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous